PEGylated Drugs Market Research Report - Global Forecast till 2027

PEGylated Drugs Market: Information by Molecule (Protein, FAB’ Fragment, Enzyme and Aptamer), by Indication (Cancer, Gout, Hemophilia and Hepatitis) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6964-CR | October 2019 | Region: Global | 103 pages

PEGylated Drugs Market Overview


PEGylated Drugs Market is expected to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.


PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings.


The major companies are rigorously investing in R&D of PEGylated drugs and have a good number of molecules in the pipeline. For instance, UCB and Biogen are evaluating the safety and efficacy of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is being developed for the treatment of systemic lupus erythematosus.


However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the PEGylated drugs market during the forecast period.


Market Dynamics


The PEGylated Drugs Market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. For instance, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer is creating a demand for effective drugs. The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the market.


 PEGylated Drugs Market Revenue, by Molecule, 2018 (% share)  PEGylated Drugs Market


Sources: MRFR Analysis


Segmentation


The PEGylated Drugs Market has been segmented into molecule, indication, and region.


On the basis of molecule, the PEGylated drugs market has been segmented into protein, enzyme, aptamer, antigen-binding fragment (FAB’ fragment) and others. PEGylated protein is estimated to account for the largest market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. For instance, in 2018, Coherus Biosciences has gained FDA approval for its Pegfilgrastim biosimilar, Udenyca (Pegfilgrastim-cbqv). Udenyca is a leukocyte growth factor used to decrease the incidence of infection in patients with non-myeloid malignancies.


On the basis of indication, the Market  for PEGylated Drugs has been segregated into cancer, hemophilia, hepatitis, gout, and others.


 PEGylated Drugs Market Share, by Region, 2018 (%)      PEGylated Drugs Market 


Sources: MRFR Analysis


Regional Analysis


The PEGylated Drugs Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas accounted for a market share of 65.73% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.


Europe was the second-largest PEGylated Drugs Market in 2018. The rising efforts by the government to reduce chronic disease burden owing to the rising occurrence of cancer in the region is projected to drive the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.


The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market.


The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.


Prominent Players


The Prominent Players in the Market are Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG. The players operating in the PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets.    


Market Segmentation


PEGylated Drugs Market, By Molecule



  • Protein

  • FAB’ Fragment

  • Enzyme

  • Aptamer


PEGylated Drugs Market, By Indication      



  • Cancer

  • Gout

  • Hemophilia

  • Hepatitis


PEGylated Drugs Market, by Region



  • North America


    • US

    • Canada




  • Latin America



  • Europe


    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe




  • Asia-Pacific


    • China

    • India

    • Japan

    • Australia & New Zealand

    • Southeast Asia

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Academic research institutes

  • Pharmaceutical companies

  • Biotechnology Companies

  • PEGylation products manufacturing companies

  • Contract research organizations (CROs)

  • Market research & consulting firms



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 13,503.67 Million
  • 2027: Significant Value
  •   CAGR   5.53% (2018-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Molecule, Indication
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG.
      Key Market Opportunities   The major companies are rigorously investing in R&D
      Key Market Drivers

  • Increase in the prevalence of chronic diseases such as cancer
  • Growing pharmaceutical industry
  • Advancements in the biologics sector


  • Frequently Asked Questions (FAQ) :


    The valuation of the global PEGylated drugs market is estimated to reach USD 13,503.67 MN. by 2025.

    The global PEGylated drugs market is projected to grow at approximately 5.53% CAGR during the forecast period (2019-2025).

    North America holds the largest share in the global PEGylated drugs market, followed by Europe and the Asia Pacific, respectively.

    F. Hoffmann-La Roche Ltd., Horizon Therapeutics Plc, Pfizer Inc., UCB S.A., Novo Nordisk A/S, Amgen, Inc., Merck & Co., Inc., AstraZeneca, Bayer AG, and Takeda Pharmaceutical Company Limited, are some of the major players operating in the PEGylated drugs market.

    1 Executive Summary

    1.1 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE 14

    1.2 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION 15

    2 Market Introduction

    2.1 DEFINITION 16

    2.2 SCOPE OF THE STUDY 16

    2.3 RESEARCH OBJECTIVE 16

    2.4 MARKET STRUCTURE 17

    3 Research Methodology

    3.1 RESEARCH PROCESS 18

    3.2 PRIMARY RESEARCH 19

    3.3 SECONDARY RESEARCH 20

    3.4 MARKET SIZE ESTIMATION 21

    3.5 FORECAST MODEL 22

    3.6 LIST OF ASSUMPTIONS 23

    4 MARKET DYNAMICS

    4.1 INTRODUCTION 24

    4.2 DRIVERS 25

    4.2.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES SUCH AS CANCER 25

    4.2.2 GROWING PHARMACEUTICAL INDUSTRY 25

    4.2.3 ADVANCEMENT IN THE BIOLOGICS SECTOR 25

    4.3 RESTRAINTS 26

    4.3.1 ADVERSE DRUG REACTIONS ASSOCIATED WITH PEGYLATED DRUGS 26

    4.3.2 DRUG RECALL 26

    4.4 OPPORTUNITIES 26

    4.4.1 STRONG PIPELINE FOR PEGYLATED DRUGS 26

    5 MARKET FACTOR ANALYSIS

    5.1 VALUE CHAIN ANALYSIS 27

    5.1.1 R&D 28

    5.1.2 MANUFACTURING 28

    5.1.3 DISTRIBUTION & SALES 28

    5.1.4 POST-SALES MONITORING 28

    5.2 PORTER’S FIVE FORCES MODEL 29

    5.2.1 THREAT OF NEW ENTRANTS 30

    5.2.2 BARGAINING POWER OF SUPPLIERS 30

    5.2.3 BARGAINING POWER OF BUYERS 30

    5.2.4 THREAT OF SUBSTITUTES 30

    5.2.5 INTENSITY OF RIVALRY 30

    6 PEGYLATED DRUGS MARKET, BY MOLECULE

    6.1 OVERVIEW 31

    6.2 PROTEIN 33

    6.3 FAB’ FRAGMENT 33

    6.4 ENZYME 34

    6.5 APTAMER 34

    7 PEGYLATED DRUGS MARKET, BY INDICATION

    7.1 OVERVIEW 35

    7.2 CANCER 37

    7.3 GOUT 37

    7.4 HEMOPHILIA 38

    7.5 HEPATITIS 38

    8 GLOBAL PEGYLATED DRUGS MARKET, BY REGION

    8.1 OVERVIEW 39

    8.2 AMERICAs 41

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.2.1 NORTH AMERICA 43

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.2.1.1 US 44

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.2.1.2 CANADA 44

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.2.2 LATIN AMERICA 45

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3 EUROPE 46

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1 WESTERN EUROPE 48

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1.1 GERMANY 49

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1.2 FRANCE 50

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1.3 UK 51

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1.4 ITALY 52

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1.5 SPAIN 53

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.1.6 REST OF WESTERN EUROPE 54

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.3.2 EASTERN EUROPE 55

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4 ASIA-PACIFIC 56

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4.1 JAPAN 58

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4.2 CHINA 59

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4.3 INDIA 60

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4.4 AUSTRALIA 61

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4.5 SOUTH KOREA 62

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.4.6 REST OF ASIA-PACIFIC 63

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.5 MIDDLE EAST & AFRICA 64

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.5.1 MIDDLE EAST 66

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    8.5.2 AFRICA 67

    PEGYLATED DRUGS MARKET, BY MOLECULE

    PEGYLATED DRUGS MARKET, BY INDICATION

    9 COMPETITIVE LANDSCAPE

    9.1 INTRODUCTION 68

    9.2 MAJOR PEGYLATED DRUGS 70

    10 COMPANY PROFILES

    10.1 HORIZON THERAPEUTICS PLC 71

    10.1.1 COMPANY OVERVIEW 71

    10.1.2 FINANCIAL OVERVIEW 71

    10.1.3 PRODUCTS/SERVICES OFFERED 72

    10.1.4 KEY DEVELOPMENTS 72

    10.1.5 SWOT ANALYSIS 73

    10.1.6 KEY STRATEGIES 73

    10.2 F. HOFFMANN-LA ROCHE LTD 74

    10.2.1 COMPANY OVERVIEW 74

    10.2.2 FINANCIAL OVERVIEW 74

    10.2.3 PRODUCTS/SERVICES OFFERED 75

    10.2.4 KEY DEVELOPMENTS 75

    10.2.5 SWOT ANALYSIS 75

    10.2.6 KEY STRATEGIES 76

    10.3 PFIZER INC. 77

    10.3.1 COMPANY OVERVIEW 77

    10.3.2 FINANCIAL OVERVIEW 77

    10.3.3 PRODUCTS/SERVICES OFFERED 78

    10.3.4 KEY DEVELOPMENTS 78

    10.3.5 SWOT ANALYSIS 79

    10.3.6 KEY STRATEGIES 79

    10.4 NOVO NORDISK A/S 80

    10.4.1 COMPANY OVERVIEW 80

    10.4.2 FINANCIAL OVERVIEW 80

    10.4.3 PRODUCTS/SERVICES OFFERED 81

    10.4.4 KEY DEVELOPMENTS 81

    10.4.5 SWOT ANALYSIS 82

    10.4.6 KEY STRATEGIES 82

    10.5 UCB S.A. 83

    10.5.1 COMPANY OVERVIEW 83

    10.5.2 FINANCIAL OVERVIEW 83

    10.5.3 PRODUCTS/SERVICES OFFERED 84

    10.5.4 KEY DEVELOPMENTS 84

    10.5.5 SWOT ANALYSIS 85

    10.5.6 KEY STRATEGIES 85

    10.6 AMGEN, INC. 86

    10.6.1 COMPANY OVERVIEW 86

    10.6.2 FINANCIAL OVERVIEW 86

    10.6.3 Products/Services Offered 87

    10.6.4 KEY DEVELOPMENTS 87

    10.6.5 KEY STRATEGIES 88

    10.7 ASTRAZENECA 89

    10.7.1 COMPANY OVERVIEW 89

    10.7.2 FINANCIAL OVERVIEW 89

    10.7.3 PRODUCTS/SERVICES OFFERED 90

    10.7.4 KEY DEVELOPMENTS 90

    10.7.5 SWOT ANALYSIS 90

    10.7.6 KEY STRATEGIES 91

    10.8 MERCK & CO., INC. 92

    10.8.1 COMPANY OVERVIEW 92

    10.8.2 FINANCIAL OVERVIEW 92

    10.8.3 PRODUCTS/SERVICES OFFERED 93

    10.8.4 KEY DEVELOPMENTS 93

    10.8.5 SWOT ANALYSIS 94

    10.8.6 KEY STRATEGIES 94

    10.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 95

    10.9.1 COMPANY OVERVIEW 95

    10.9.2 FINANCIAL OVERVIEW 95

    10.9.3 PRODUCTS/SERVICES OFFERED 96

    10.9.4 KEY DEVELOPMENTS 96

    10.9.5 SWOT ANALYSIS 96

    10.9.6 KEY STRATEGIES 97

    10.10 BAYER AG 98

    10.10.1 COMPANY OVERVIEW 98

    10.10.2 FINANCIAL OVERVIEW 98

    10.10.3 PRODUCTS/SERVICES OFFERED 99

    10.10.4 KEY DEVELOPMENTS 99

    10.10.5 SWOT ANALYSIS 99

    10.10.6 KEY STRATEGIES 100

    11 APPENDIX

    11.1 REFERENCES 101

    11.2 RELATED REPORTS 101

    12 List of Tables

    TABLE 1 PRIMARY INTERVIEWS 19

    TABLE 2 LIST OF ASSUMPTIONS 23

    TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE 2020–2027 (USD MILLION) 32

    TABLE 4 PROTEIN: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 33

    TABLE 5 FAB’ FRAGMENT: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 33

    TABLE 6 ENZYME: MARKET ESTIMATES & FORECAST, BY REGION, 2020-2027 (USD MILLION) 34

    TABLE 7 APTAMER: MARKET ESTIMATES & FORECAST, BY REGION, 2020-2027 (USD MILLION) 34

    TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION 2020–2027 (USD MILLION) 36

    TABLE 9 CANCER: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 37

    TABLE 10 GOUT: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 37

    TABLE 11 HEMOPHILIA: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 38

    TABLE 12 HEPATITIS: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 38

    TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 40

    TABLE 14 AMERICAS: PEGYLATED DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 41

    TABLE 15 AMERICAS: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 42

    TABLE 16 AMERICAS: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 42

    TABLE 17 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 43

    TABLE 18 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 43

    TABLE 19 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 43

    TABLE 20 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 44

    TABLE 21 US: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 44

    TABLE 22 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 44

    TABLE 23 CANADA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 45

    TABLE 24 LATIN AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 45

    TABLE 25 LATIN AMERICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 45

    TABLE 26 EUROPE: PEGYLATED DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 46

    TABLE 27 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 47

    TABLE 28 EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 47

    TABLE 29 WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 48

    TABLE 30 WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 48

    TABLE 31 WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 48

    TABLE 32 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 49

    TABLE 33 GERMANY: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 49

    TABLE 34 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 50

    TABLE 35 FRANCE: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 50

    TABLE 36 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 51

    TABLE 37 UK: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 51

    TABLE 38 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 52

    TABLE 39 ITALY: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 52

    TABLE 40 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 53

    TABLE 41 SPAIN: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 53

    TABLE 42 REST OF WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 54

    TABLE 43 REST OF WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 54

    TABLE 44 EASTERN EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 55

    TABLE 45 EASTERN EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 55

    TABLE 46 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 56

    TABLE 47 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 57

    TABLE 48 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 57

    TABLE 49 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 58

    TABLE 50 JAPAN: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 58

    TABLE 51 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 59

    TABLE 52 CHINA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 59

    TABLE 53 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 60

    TABLE 54 INDIA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 60

    TABLE 55 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 61

    TABLE 56 AUSTRALIA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 61

    TABLE 57 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 62

    TABLE 58 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 62

    TABLE 59 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 63

    TABLE 60 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 63

    TABLE 61 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 64

    TABLE 62 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 65

    TABLE 63 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 65

    TABLE 64 MIDDLE EAST: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 66

    TABLE 65 MIDDLE EAST: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 66

    TABLE 66 AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 67

    TABLE 67 AFRICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 67

    TABLE 68 MAJOR PEGYLATED DRUGS 70

    TABLE 69 PRODUCTS/SERVICES OFFERED 72

    TABLE 70 KEY DEVELOPMENTS 72

    TABLE 71 PRODUCTS PRODUCTS/SERVICES OFFERED 75

    TABLE 72 PRODUCTS/SERVICES OFFERED 78

    TABLE 73 KEY DEVELOPMENTS 78

    TABLE 74 PRODUCTS/SERVICES OFFERED 81

    TABLE 75 KEY DEVELOPMENTS 81

    TABLE 76 PRODUCTS/SERVICES OFFERED 84

    TABLE 77 KEY DEVELOPMENTS 84

    TABLE 78 PRODUCTS/SERVICES OFFERED 87

    TABLE 79 PRODUCTS/SERVICES OFFERED 90

    TABLE 80 PRODUCTS/SERVICES OFFERED 93

    TABLE 81 KEY DEVELOPMENTS 93

    TABLE 82 PRODUCTS/SERVICES OFFERED 96

    TABLE 83 KEY DEVELOPMENTS 96

    TABLE 84 PRODUCTS/SERVICES OFFERED 99

    TABLE 85 KEY DEVELOPMENTS 99

    13 List of Figures

    FIGURE 1 MARKET SYNOPSIS 13

    FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET ANALYSIS, BY MOLECULE 14

    FIGURE 3 GLOBAL PEGYLATED DRUGS MARKET ANALYSIS, BY INDICATION 15

    FIGURE 4 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE 17

    FIGURE 5 RESEARCH PROCESS 18

    FIGURE 6 TOP-DOWN & BOTTOM-UP APPROACHES 21

    FIGURE 7 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PEGYLATED DRUGS MARKET 24

    FIGURE 8 SUPPLY/VALUE CHAIN: GLOBAL PEGYLATED DRUGS MARKET 27

    FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2020 (% SHARE) 31

    FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2020 TO 2027 (USD MILLION) 32

    FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION, 2020 (% SHARE) 35

    FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION, 2020 TO 2027 (USD MILLION) 36

    FIGURE 14 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 39

    FIGURE 15 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2020 (% SHARE) 40

    FIGURE 16 AMERICAS: PEGYLATED DRUGS MARKET SHARE, BY REGION, 2020 (% SHARE) 41

    FIGURE 17 EUROPE: PEGYLATED DRUGS MARKET SHARE, BY REGION, 2020 (% SHARE) 46

    FIGURE 18 ASIA-PACIFIC: PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2020 (% SHARE) 56

    FIGURE 19 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET SHARE, BY REGION, 2020 (% SHARE) 64

    FIGURE 20 GLOBAL PEGYLATED DRUGS MARKET, SHARE ANALYSIS, 2020 (% SHARE) 68

    FIGURE 21 FINANCIAL OVERVIEW SNAPSHOT 71

    FIGURE 22 SWOT ANALYSIS 73

    FIGURE 23 FINANCIAL OVERVIEW SNAPSHOT 74

    FIGURE 24 SWOT ANALYSIS 75

    FIGURE 25 FINANCIAL OVERVIEW SNAPSHOT 77

    FIGURE 26 SWOT ANALYSIS 79

    FIGURE 27 FINANCIAL OVERVIEW SNAPSHOT 80

    FIGURE 28 SWOT ANALYSIS 82

    FIGURE 29 FINANCIAL OVERVIEW SNAPSHOT 83

    FIGURE 30 SWOT ANALYSIS 85

    FIGURE 31 FINANCIAL OVERVIEW SNAPSHOT 86

    FIGURE 32 SWOT ANALYSIS 87

    FIGURE 33 FINANCIAL OVERVIEW SNAPSHOT 89

    FIGURE 34 SWOT ANALYSIS 90

    FIGURE 35 FINANCIAL OVERVIEW SNAPSHOT 92

    FIGURE 36 SWOT ANALYSIS 94

    FIGURE 37 FINANCIAL OVERVIEW SNAPSHOT 95

    FIGURE 38 SWOT ANALYSIS 96

    FIGURE 39 FINANCIAL OVERVIEW SNAPSHOT 98

    FIGURE 40 SWOT ANALYSIS 99



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.